Earnings per share for the last twelve months: CytoMed Therapeutics Ltd (GDTC)
The prospects for CytoMed Therapeutics (GDTC) depend on the trial stages of cell therapy, as confirmed by the TTM earnings per share chart from the GURU.Markets platform, where the -0.23 level serves as a critical mark. While geopolitical barriers and sanctions hinder the international exchange of biomaterials, leadership in immuno-oncology and massive R&D investments in NK-cell development allow the company to minimize these risks.
Analytical breakdowns and data insights for company w2.cytomed.sg (GDTC)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio CytoMed Therapeutics|GDTC - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio CytoMed|GDTC - Company Cumulative Indebtedness|Debt to Book Capitalization Ratio CytoMed Therapeutics Limited|GDTC - Long-Term Debt|Company Short-Term Debt CytoMed Therapeutics|Quick Ratio w2.cytomed.sg
- net income and valuation multiples indicators:
GDTC - Company Net Income|Projected Future Earnings CytoMed Therapeutics|GDTC - Price to Earnings Multiple|Projected Price to Earnings CytoMed Therapeutics Limited|GDTC - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio CytoMed Therapeutics Limited|GDTC - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) CytoMed Therapeutics|GDTC - Earnings per share for the trailing year|Quarterly EPS earnings growth w2.cytomed.sg|GDTC - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year CytoMed Therapeutics
- revenue and sales proceeds data:
Summary company analytics:GDTC - w2.cytomed.sg
Long-term investing requires protection against value traps when searching for local bottoms. For CytoMed Therapeutics (GDTC), which focuses on cellular oncology therapy with strict biomaterial disposal regulations, financial stability is critical. The EPS TTM history reflects net income distributed per share over a year, excluding speculative noise. This metric measures real business efficiency, stripped of the impact of issuance. The stability of this indicator confirms the fundamental viability of the company.
Main competitors
ONC - Earnings per share for the last twelve months|HALO - Net earnings per share (EPS TTM)|RevMed (RVMD) - Earnings per share for the last twelve months|Ascentage - Earnings per share for the trailing year|CGON (CG Oncology Inc) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months UroGen Pharma URGN|Net earnings per share (EPS TTM) BCAX|PSNL: Earnings per one share for the last 12 months|Earnings per share for the last twelve months Erasca Corp ERAS|Delcath Corp (DCTH) - Net earnings per one share for the last twelve months|YMAB - Earnings per share for the last twelve months|Earnings per share for the trailing year AURA (Aura Biosciences, Inc.)|CADL: Net earnings per share (EPS TTM)|Accuray Inc (ARAY) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months SELLAS Life Sciences Group|Net earnings per share (EPS TTM) Actuate Therapeutics, Inc.|Earnings per share for the last twelve months citiusonc.com (CTOR)|Net earnings per share (EPS TTM) TuHURA (HURA)|Net earnings per share (EPS TTM) TARA (protaratx.com)|Earnings per share for the trailing year FATE|WHWK - Earnings per share for the last twelve months|Earnings per share for the trailing year TCRX (tscan.com)|Champions Oncology (CSBR) - Earnings per share for the last twelve months|XBiotech Inc - Earnings per share for the trailing year|Earnings per share for the last twelve months cel-sci.com|OS Therapies (OSTX) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months RADX (Radiopharm Theranostics Limited)|Earnings per share for the last four quarters ARTV|Adlai Nortye Ltd. - Net earnings per share for the last 12 months|Earnings per share for the trailing year VERU|tempesttx.com - Net earnings per share (EPS TTM)|XLO - Net earnings per share (EPS TTM)|Enochian BioSciences (RENB) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Mural Oncology plc (MURA)|Earnings per share for the last twelve months Kairos Pharma Ltd|Net earnings per share (EPS TTM) OnKure Therapeutics|Net earnings per share (EPS TTM) CRIS|Net earnings per share (EPS TTM) Apollomics Inc. (APLM)|Net earnings per share (EPS TTM) THAR (Tharimmune Corp)|Net earnings per share for the last four quarters Advanced Biomed Inc (ADVB)|Genprex Inc - Net earnings per share (EPS TTM)|CLDI - Net earnings per share (EPS TTM)|Sunshine Biopharma Inc. (SBFM) - Earnings per share for the last twelve months|XBIO - Net earnings per share for the last four quarters|SLRX (Salarius Pharma) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Kitov Pharma|Net earnings per share for the last 12 months AONC (American Oncology Network)|BGNE - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) CKPT (Checkpoint Therapeutics Inc.)|Elevation Oncology, Inc. - Earnings per share for the last twelve months|ICAD - Earnings per share for the last twelve months|IKNA - Net earnings per share (EPS TTM)|Notable Labs (NTBL) - Earnings per share for the last twelve months|Earnings per share for the last 12 months VIRX|MOR (MorphoSys Corporation) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NAYA Biosciences Inc NAYA|Earnings per share for the last twelve months Ascentage Pharma (AAPGV)
